145 related articles for article (PubMed ID: 37474984)
1. [Ginsenoside Rg_3 based liposomes target delivery of dihydroartemisinin and paclitaxel for treatment of triple-negative breast cancer].
Liu H; Liu Y; Li N; Zhang GQ; Wang M
Zhongguo Zhong Yao Za Zhi; 2023 Jul; 48(13):3472-3484. PubMed ID: 37474984
[TBL] [Abstract][Full Text] [Related]
2. Novel ginsenoside-based multifunctional liposomal delivery system for combination therapy of gastric cancer.
Hong C; Wang D; Liang J; Guo Y; Zhu Y; Xia J; Qin J; Zhan H; Wang J
Theranostics; 2019; 9(15):4437-4449. PubMed ID: 31285771
[TBL] [Abstract][Full Text] [Related]
3. Unfolding the Potency of Adenosine in Targeting Triple Negative Breast Cancer via Paclitaxel-Incorporated pH-Responsive Stealth Liposomes.
Chaudhari D; Katari O; Ghadi R; Kuche K; Date T; Bhargavi N; Jain S
ACS Biomater Sci Eng; 2022 Aug; 8(8):3473-3484. PubMed ID: 35896042
[TBL] [Abstract][Full Text] [Related]
4. Dual-targeting liposomes with active recognition of GLUT
Pu Y; Zhang H; Peng Y; Fu Q; Yue Q; Zhao Y; Guo L; Wu Y
Eur J Med Chem; 2019 Dec; 183():111720. PubMed ID: 31553933
[TBL] [Abstract][Full Text] [Related]
5. EGFR Targeted Paclitaxel and Piperine Co-loaded Liposomes for the Treatment of Triple Negative Breast Cancer.
Burande AS; Viswanadh MK; Jha A; Mehata AK; Shaik A; Agrawal N; Poddar S; Mahto SK; Muthu MS
AAPS PharmSciTech; 2020 May; 21(5):151. PubMed ID: 32440910
[TBL] [Abstract][Full Text] [Related]
6. Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-κB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer.
Yuan Z; Jiang H; Zhu X; Liu X; Li J
Biomed Pharmacother; 2017 May; 89():227-232. PubMed ID: 28231544
[TBL] [Abstract][Full Text] [Related]
7. Assessment of a New Ginsenoside Rh2 Nanoniosomal Formulation for Enhanced Antitumor Efficacy on Prostate Cancer: An in vitro Study.
Zare-Zardini H; Alemi A; Taheri-Kafrani A; Hosseini SA; Soltaninejad H; Hamidieh AA; Haghi Karamallah M; Farrokhifar M; Farrokhifar M
Drug Des Devel Ther; 2020; 14():3315-3324. PubMed ID: 32884236
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel-loaded ginsenoside Rg3 liposomes for drug-resistant cancer therapy by dual targeting of the tumor microenvironment and cancer cells.
Zhu Y; Wang A; Zhang S; Kim J; Xia J; Zhang F; Wang D; Wang Q; Wang J
J Adv Res; 2023 Jul; 49():159-173. PubMed ID: 36167294
[TBL] [Abstract][Full Text] [Related]
9. Pegylated liposomal encapsulation improves the antitumor efficacy of combretastatin A4 in murine 4T1 triple-negative breast cancer model.
Mirzavi F; Barati M; Vakili-Ghartavol R; Roshan MK; Mashreghi M; Soukhtanloo M; Jaafari MR
Int J Pharm; 2022 Feb; 613():121396. PubMed ID: 34942328
[TBL] [Abstract][Full Text] [Related]
10. Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy.
Eloy JO; Petrilli R; Topan JF; Antonio HMR; Barcellos JPA; Chesca DL; Serafini LN; Tiezzi DG; Lee RJ; Marchetti JM
Colloids Surf B Biointerfaces; 2016 May; 141():74-82. PubMed ID: 26836480
[TBL] [Abstract][Full Text] [Related]
11. Targeted Delivery of Combination Therapeutics Using Monoclonal Antibody 2C5-Modified Immunoliposomes for Cancer Therapy.
Narayanaswamy R; Torchilin VP
Pharm Res; 2021 Mar; 38(3):429-450. PubMed ID: 33655395
[TBL] [Abstract][Full Text] [Related]
12. Preparation, Characterization, and Pharmacokinetic Study of a Novel Long-Acting Targeted Paclitaxel Liposome with Antitumor Activity.
Han B; Yang Y; Chen J; Tang H; Sun Y; Zhang Z; Wang Z; Li Y; Li Y; Luan X; Li Q; Ren Z; Zhou X; Cong D; Liu Z; Meng Q; Sun F; Pei J
Int J Nanomedicine; 2020; 15():553-571. PubMed ID: 32158208
[TBL] [Abstract][Full Text] [Related]
13. [Preparation of warangalone-loaded liposomes and its inhibitory effect on breast cancer cells].
Mao L; Liu H; Liu H; Bian Z; Zhang Q; Liao W; Sun S
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Jun; 40(6):876-883. PubMed ID: 32895205
[TBL] [Abstract][Full Text] [Related]
14. Ginsenoside Rg3 liposomes regulate tumor microenvironment for the treatment of triple negative breast cancer.
Miao L; Ma H; Dong T; Zhao C; Gao T; Wu T; Xu H; Zhang J
Drug Dev Ind Pharm; 2023 Jan; 49(1):139-148. PubMed ID: 36881020
[TBL] [Abstract][Full Text] [Related]
15. Ginsenoside Rb1 stabilized and paclitaxel / protopanaxadiol co-loaded nanoparticles for synergistic treatment of breast tumor.
Lu L; Ao H; Fu J; Li M; Guo Y; Guo Y; Han M; Shi R; Wang X
Biomed Pharmacother; 2023 Jul; 163():114870. PubMed ID: 37187019
[TBL] [Abstract][Full Text] [Related]
16. Targeting therapy and tumor microenvironment remodeling of triple-negative breast cancer by ginsenoside Rg3 based liposomes.
Xia J; Zhang S; Zhang R; Wang A; Zhu Y; Dong M; Ma S; Hong C; Liu S; Wang D; Wang J
J Nanobiotechnology; 2022 Sep; 20(1):414. PubMed ID: 36109762
[TBL] [Abstract][Full Text] [Related]
17. Improved safety and efficacy of a lipid emulsion loaded with a paclitaxel-cholesterol complex for the treatment of breast tumors.
Ye J; Liu Y; Xia X; Meng L; Dong W; Wang R; Fu Z; Liu H; Han R
Oncol Rep; 2016 Jul; 36(1):399-409. PubMed ID: 27175803
[TBL] [Abstract][Full Text] [Related]
18. Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy.
Eloy JO; Petrilli R; Chesca DL; Saggioro FP; Lee RJ; Marchetti JM
Eur J Pharm Biopharm; 2017 Jun; 115():159-167. PubMed ID: 28257810
[TBL] [Abstract][Full Text] [Related]
19. Ginsenoside Rh2-Based Multifunctional Liposomes for Advanced Breast Cancer Therapy.
Hong C; Wang A; Xia J; Liang J; Zhu Y; Wang D; Zhan H; Feng C; Jiang X; Pan J; Wang J
Int J Nanomedicine; 2024; 19():2879-2888. PubMed ID: 38525007
[TBL] [Abstract][Full Text] [Related]
20. Coaxial electrostatic spray-based preparation of localization missile liposomes on a microfluidic chip for targeted treatment of triple-negative breast cancer.
Wang Q; Xu W; Li Q; He C; Liu Y; Liu J; Wang R; Wu J; Xiang D; Chen C
Int J Pharm; 2023 Aug; 643():123220. PubMed ID: 37437856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
